Charles River Laboratories (CRL) faces significant headwinds with a revenue growth of -0.85% year-over-year and a negative return on equity (ROE) of -4.40%. Despite a current price of $175.07, which is up 3.26% from the previous close of $169.54, the stock's performance is dampened by its high P/B ratio of 3.16 and a beta of 1.58, indicating higher volatility compared to the market.